Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hut 8 Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Hut 8 Corp trades at $91.01 (market cap $10.56B). The key difference: Hut 8 Corp is far larger — about 12.2× Amphastar Pharmaceuticals Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | HUT | |
|---|---|---|
Market Cap | $863.95M | $10.56B |
Sector | Health | Technology |
52-Week High | $30.81 | $133.02 |
52-Week Low | $16.87 | $20.57 |
Enterprise Value | $1.26B | $17.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
HUT trades at $88.59, down 2.27% today amid bearish technical signals and mixed quarterly earnings. The stock faces headwinds from negative net income margins and cash burn, but maintains strong analyst support with a 93.75% buy rating and a $165.11 consensus price target. Recent news highlights institutional accumulation and a strategic pivot to AI data centers, backed by a $26.6 billion contracted backlog.
Outlook hinges on execution of AI infrastructure projects, offering substantial upside if targets are met, but high valuation multiples and persistent losses pose risks. Investors must weigh growth potential against financial sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
